Seminars in Nuclear Medicine
Volume 39, Issue 3 , Pages 204-209 , May 2009

Current Advances in Vasodilator Pharmacological Stress Perfusion Imaging

  • Regina S. Druz, MD, FACC, FASNC

      Affiliations

    • Nuclear Cardiology, North Shore University Hospital, Manhasset, NY
    • New York University School of Medicine, New York, NY
    • Corresponding Author InformationAddress reprint requests to Regina S. Druz, MD, FACC, FASNC, Nuclear Cardiology, North Shore University Hospital, 300 Community Drive, Manhasset, NY 11030

References 

  1. Astellas Pharma Internal Reports. Deerfield, IL: Astellas Pharma US; 2008;
  2. Bokhari S, Ficaro EP, McCallister BD. Adenosine stress protocols for myocardial perfusion imaging. J Nucl Cardiol. 2007;14:415–416
  3. Adenoscan (adenosine injection) package insert. Deerfield, IL: Astellas Pharma, US, Inc; 2005;
  4. Henzlova MJ, Cerqueira MD, Mahmarian JJ, et al. Stress protocols and tracers. J Nucl Cardiol. 2006;13:e80–e90
  5. Klodas E, Miller TD, Christian TF, et al. Prognostic significance of ischemic electrocardiographic changes during vasodilator stress testing in patients with normal SPECT images. J Nucl Cardiol. 2003;10:4–8
  6. Kaufmann PA. Differential effects of pharmacological stressors: More than meets the eye. J Nucl Cardiol. 2006;13:311–312
  7. Druz RS, Akinboboye OA, Grimson R, et al. Postischemic stunning after adenosine vasodilator stress. J Nucl Cardiol. 2004;11:534–541
  8. Hachamovitch R, Berman DS, Kiat H, et al. Incremental prognostic value of adenosine stress myocardial perfusion single-photon emission computed tomography and impact on subsequent management in patients with or suspected of having myocardial ischemia. Am J Cardiol. 1997;80:426–433
  9. Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: Differential stratification for risk of cardiac death and myocardial infarction. Circulation. 1998;97:535–543
  10. Gao Z, Li Z, Baker SP, et al. Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther. 2001;298:209–218
  11. Lexiscan (regadenoson injection) package insert. Deerfield, IL: Astellas Pharma, US, Inc; 2008;
  12. Cerqueira MC, Nguyen P, et al. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective a2a agonist regadenoson versus adenosine in myocardial perfusion imaging: Integrated ADVANCE-MPI Trial Results. JACC Cardiovascular Imaging. 2008;1:307–316
  13. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539–542
  14. Laighold S, Druz R: Initial clinical experience with a selective A2A receptor agonist, Regadenoson, in a patient with end-stage renal disease on hemodialysis. J Nucl Cardiol (in press)
  15. Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol. 2007;47:825–833
  16. Mahmarian JJ, Shaw LJ, Filipchuk NG, et al. A multinational study to establish the value of early adenosine technetium-99m sestamibi myocardial perfusion imaging in identifying a low-risk group for early hospital discharge after acute myocardial infarction. J Am Coll Cardiol. 2006;48:2448–2457
  17. Mahmarian JJ, Dakik HA, Filipchuk NG, et al. An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction. J Am Coll Cardiol. 2006;48:2458–2467
  18. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117:1283–1291
  19. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516

PII: S0001-2998(08)00139-6

doi: 10.1053/j.semnuclmed.2008.12.003

Seminars in Nuclear Medicine
Volume 39, Issue 3 , Pages 204-209 , May 2009

Article Tools

* Image Usage & Resolution